Context-dependent regulation of lipid homeostasis by miR-122: Molecular mechanisms, disease relevance, and therapeutic implications

Scritto il 14/11/2026
da Mengpu Wu

Biochem Pharmacol. 2026 Nov 14:118659. doi: 10.1016/j.bcp.2026.118659. Online ahead of print.

ABSTRACT

miR-122 is a liver-enriched microRNA that shapes systemic lipid homeostasis by coordinating hepatic de novo lipogenesis, oxidative disposal, intracellular storage, and lipoprotein export. Mechanistically, miR-122 intersects with energy-sensing pathways centered on AMPK, modulates lipogenesis through Sirtuin-LKB1/AMPK control, influences triglyceride handling via YY1-linked transcriptional programs, and engages noncoding RNA circuits that regulate autophagy. Furthermore, intracellular miR-122 regulates lipid peroxidation (ferroptosis) in a highly context-dependent manner: it buffers against oxidative injury in steatotic hepatocytes and ischemic tissue injuries, yet actively promotes ferroptosis by targeting SLC7A11 and GPX4 in hepatocellular carcinoma and autoimmune hepatitis. Meanwhile, extracellular vesicle (EV)-associated miR-122 mediates pathogenic inter-organ metabolic communication. Clinically, the progressive decline of hepatic miR-122 drives the transition from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC), positioning circulating miR-122 as a highly sensitive diagnostic biomarker. Short-term antagonism via locked nucleic acid (LNA)-based anti-miRs efficiently lowers circulating cholesterol, yet preclinical models suggest that prolonged suppression risks progressive hepatic inflammatory remodeling and steatofibrosis. Conversely, for advanced liver diseases characterized by miR-122 depletion, miR-122 replacement therapies show potential to restore metabolic resilience and suppress fibrogenesis. This review synthesizes current mechanistic evidence and highlights the development of miR-122-targeted nucleic acid drugs and the therapeutic exploitation of exosomal vectors, providing a translational scene for managing lipid-driven metabolic and hepatic disorders.

PMID:43033934 | DOI:10.1016/j.bcp.2026.118659